OSU-2S

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2016
0120112016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
OSU-2S is a FTY720 (Fingolimod) derivative that lacks immunosuppressive properties but exhibits strong anti-tumour activity in… (More)
  • figure 1
Is this relevant?
2017
2017
The successful targeting of different malignancies by OSU-2S, encouraged us to design and synthesize a novel series of… (More)
Is this relevant?
2016
2016
Background: Sorafenib (Nexavar®) is an FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). However, the… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Mantle-cell lymphoma (MCL) remains incurable despite numerous therapeutic advances. OSU-2S, a novel nonimmunosuppressive FTY720… (More)
  • figure 1
  • figure 2
Is this relevant?
2015
2015
Selective cytotoxicity to cancer cells without compromising their normal counterparts pose a huge challenge for traditional drug… (More)
Is this relevant?
2014
2014
OSU-2S is a novel anti-cancer and immune modulatory agent designed specifically to avert the immunosuppressive effects and… (More)
  • table 2
Is this relevant?
2011
2011
UNLABELLED Accumulating evidence suggests the therapeutic potential of the immunosuppressive agent FTY720 (fingolimod) in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 6
Is this relevant?